

Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/PD23B5A27E7BEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PD23B5A27E7BEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Platelet-derived growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Platelet-derived growth factor receptor antagonists Understanding

Platelet-derived growth factor receptor antagonists: Overview

Platelet-derived growth factor receptors belong to class III receptor tyrosine kinases. In human, there are four genes expressing PDGF chains: PDGF-A, B, C and D. PDGFA, PDGFB, PDGFC, and PDGFD genes are located on chromosomes 7, 22, 4, and 11, respectively. Platelet-derived growth factor plays a significant role in cell proliferation and embryonic development and is regulated through the platelet-derived growth factor receptor (PDGFR). Platelet-derived growth factor receptor (PDGFR) is a compelling target for developing therapeutic agents to treat diseases associated with overactivated platelet-derived growth factor (PDGF) signaling and has proved to be particularly

encouraging for cancer treatment.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Platelet-derived growth factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Platelet-derived growth factor receptor antagonists.

Platelet-derived growth factor receptor antagonists Emerging Drugs Chapters

This segment of the Platelet-derived growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Platelet-derived growth factor receptor antagonists Emerging Drugs

Lenvatinib: Eisai

Lenvatinib (LENVIMA) is orally available multi-kinase inhibitor and antineoplastic agent that is used in treatment of advanced, metastatic medullary thyroid cancer and refractory renal cell carcinoma. LENVIMA is also used as the first treatment for hepatocellular carcinoma. The drug is in clinical development for other cancers and solid tumors.

Quizartinib: Daiichi Sankyo Company

Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Quizartinib is use for acute myeloid leukemia treatment and is in clinical development for Myelodysplastic syndromes and Precursor cell lymphoblastic

leukaemia-lymphoma.

Further product details are provided in the report.....

Platelet-derived growth factor receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Platelet-derived growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Platelet-derived growth factor receptor antagonists

There are approx. 8+ key companies which are developing the Platelet-derived growth factor receptor antagonists. The companies which have their Platelet-derived growth factor receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Eisai.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Platelet-derived growth factor receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products

have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Platelet-derived growth factor receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Platelet-derived growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Platelet-derived growth factor receptor antagonists drugs.

Platelet-derived growth factor receptor antagonists Report Insights

Platelet-derived growth factor receptor antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Platelet-derived growth factor receptor antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Platelet-derived growth factor receptor antagonists drugs?

How many Platelet-derived growth factor receptor antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Platelet-derived growth factor receptor antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Platelet-derived growth factor receptor antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Platelet-derived growth factor receptor antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eisai

Daiichi Sankyo Company

Jiangsu Hengrui Medicine

Boehringer Ingelheim

Betta Pharmaceuticals

Tyrogenex

Pfizer

Metagone Biotech

Bayer Healthcare

AROG Pharmaceuticals

Pfizer

Molecular Partners

Xspray Pharma

Key Products

Lenvatinib

Quizartinib

Famitinib

Nintedanib

Vorolanib

Axitinib

MGD 1509

Regorafenib

Crenolanib

AGN-151200

Sorafenib nanoparticle formulation

Contents

Introduction

Executive Summary

Platelet-derived growth factor receptor antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Platelet-derived growth factor receptor antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Platelet-derived growth factor receptor antagonists companies' collaborations, Licensing, Acquisition -Deal Value Trends

Platelet-derived growth factor receptor antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Lenvatinib: Eisai

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II/III)

Comparative Analysis

Quizartinib: Daiichi Sankyo Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

AGN-151200: Molecular Partners AG

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Platelet-derived growth factor receptor antagonists Key Companies

Platelet-derived growth factor receptor antagonists Key Products

Platelet-derived growth factor receptor antagonists- Unmet Needs

Platelet-derived growth factor receptor antagonists- Market Drivers and Barriers

Platelet-derived growth factor receptor antagonists- Future Perspectives and

Conclusion

Platelet-derived growth factor receptor antagonists Analyst Views

Platelet-derived growth factor receptor antagonists Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Platelet-derived growth factor receptor antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Platelet-derived growth factor receptor antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PD23B5A27E7BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD23B5A27E7BEN.html>